Nasdaq:ALRN

— Several existing Aileron investors, including Satter Medical Technology Partners and Lincoln Park Capital Fund, LLC, also participated in the offering

WATERTOWN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) — Aileron Therapeutics, Inc. (Nasdaq: ALRN), today announced that it has entered into

Presented positive clinical proof-of-concept data from ongoing ALRN-6924 Phase 1b trial in patients with p53-mutated small cell lung cancer (SCLC)

Presented positive clinical proof-of-concept data from ongoing ALRN-6924 Phase 1b trial in patients with p53-mutated small cell lung cancer (SCLC)

First and only chemoprotective therapy in clinical development that utilizes a biomarker strategy designed to protect patients with p53-mutated cancers

WATERTOWN, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN) today announced that it will host a conference

Aileron aims to create new paradigm of proactive prevention of chemotherapy-induced side effects to address significant unmet need among cancer

WATERTOWN, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) — Aileron Therapeutics, Inc. (NASDAQ: ALRN), today announced it has entered into a common

WATERTOWN, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) — Aileron Therapeutics, Inc. (NASDAQ: ALRN), today announced it has entered into a common

WATERTOWN, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) — Aileron Therapeutics, Inc. (NASDAQ: ALRN), today announced it has entered into a common